









Markets
/
Stocks
/
nasdaq-adxn
/

Addex Therapeutics Ltd

ADXN

7.900USD

-0.190-2.47%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

7.67MMarket Cap

LossP/E TTM



Addex Therapeutics Ltd

7.900

-0.190-2.47%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Addex Therapeutics Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Addex Therapeutics Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 235 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 30.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Addex Therapeutics Ltd's Score

Industry at a Glance

Industry Ranking

235 / 392

Overall Ranking

515 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Addex Therapeutics Ltd Highlights

StrengthsRisks

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Growing

The company is in a growing phase, with the latest annual income totaling USD 465.76K.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -0.94, at a low 3-year percentile range.

Analyst Rating

Based on 0 analysts

Current Rating

30.000

Target Price

+243.64%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Addex Therapeutics Ltd is 6.11, ranking 287 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 62.01K, representing a year-over-year decrease of 7.97%, while its net profit experienced a year-over-year decrease of 11.60%.

Score

Industry at a Glance

Previous score

6.11

Change



Financials

8.12

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.68

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Addex Therapeutics Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Addex Therapeutics Ltd is 1.00, ranking 387 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.94, which is -370.49% below the recent high of 2.55 and -62.55% above the recent low of -1.53.

Score

Industry at a Glance

Previous score

1.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 235/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Addex Therapeutics Ltd. The Biotechnology & Medical Research industry's average is 8.05. The average price target is 30.00, with a high of 30.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Addex Therapeutics Ltd is 6.97, ranking 127 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.93 and the support level at 6.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.88

Change

0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.048

Sell

RSI(14)

49.272

Neutral

STOCH(KDJ)(9,3,3)

56.430

Buy

ATR(14)

0.422

Low Volatility

CCI(14)

-20.807

Neutral

Williams %R

44.828

Buy

TRIX(12,20)

-0.123

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

7.776

Buy

MA10

7.817

Buy

MA20

8.008

Sell

MA50

7.961

Sell

MA100

8.495

Sell

MA200

8.386

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

UBS Financial Services, Inc.

1.00

GAMMA Investing LLC

81.00

-33.06%

Rhumbline Advisers Ltd. Partnership

72.00

SBI Securities Co., Ltd.

5.00

Citadel Advisors LLC

-100.00%

Morgan Stanley & Co. LLC

-100.00%

Adar1 Capital Management LLC

-100.00%

J.P. Morgan Securities LLC

-100.00%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Addex Therapeutics Ltd is 1.91, ranking 269 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.46. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.